Literature DB >> 11358166

The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada.

F E Ashton1, D A Caugant.   

Abstract

Three hundred and one (301) strains of Neisseria meningitidis serogroup B, isolated from patients with meningococcal disease during the years 1994-1996, were subjected to multilocus enzyme electrophoresis, serotyping, and serosubtyping. Based on the analyses of 14 enzyme loci, 177 electrophoretic types (ETs) were identified. Of these, 136 were represented by single isolates and 41 were represented by multiple isolates (range 2-31). The mean genetic diversity for isolates was 0.444 and for ETs was 0.440. The index of association (I(A)) between loci was 0.530 +/- 0.08 for isolates and 0.256 +/- 0.10 for ETs. Cluster analysis revealed the presence of 39 lineages each represented by a single ET or clusters of ETs. The most common serotypes were 4, 15, and 14 and accounted for 84 (28.0%), 53 (17.6%), and 32 (10.6%) of the isolates, respectively, and were dispersed amongst 46 ETs (1-122), 35 ETs (3-165), and 26 ETs (18-76), respectively. The 109 (36.6%) nontypable (NT) isolates were amongst 74 ETs (6-177). The mean genetic diversity for serotypes 4, 15, and 14 and NT isolates was 0.368, 0.371, 0.343, and 0.442, respectively, and for ETs was 0.363, 0.354, 0.397, and 0.440, respectively. Combinations of serotypes and serosubtypes (number of isolates) that occurred most frequently were 4:P1.14 (17), 14:P1.16 (16), NT:P1.16 (16), 15:P1.16 (13), and NT:P1.13 (13). The majority of group B disease in Canada during 1994-1996 was caused by meningococci of considerable genetic diversity, and reflects a situation of endemic disease. However, the results also indicate that organisms belonging to the ET-5 complex, which has been responsible for outbreaks of group B disease globally for several decades, have been introduced into the country.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358166

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  6 in total

1.  Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001.

Authors:  Raymond Sw Tsang; Susan G Squires; Wendell D Zollinger; Fraser E Ashton
Journal:  Can J Infect Dis       Date:  2002-11

2.  Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

Authors:  Dennis K S Law; Manon Lorange; Louise Ringuette; Réjean Dion; Michel Giguère; Averil M Henderson; Jan Stoltz; Wendell D Zollinger; Philippe De Wals; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

4.  Antimicrobial susceptibility, serotype and genotype distribution of meningococci in Portugal, 2001-2002.

Authors:  E Ferreira; R Dias; M Caniça
Journal:  Epidemiol Infect       Date:  2006-06-02       Impact factor: 2.451

5.  Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada.

Authors:  Raymond S W Tsang; Chao Ming Tsai; Peixuan Zhu; Louise Ringuette; Manon Lorange; Dennis K S Law
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

6.  The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.

Authors:  Rodica Gilca; Geneviève Deceuninck; Brigitte Lefebvre; Raymond Tsang; Rachid Amini; Vladimir Gilca; Monique Douville-Fradet; France Markowski; Philippe De Wals
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.